Pediatric clinicians routinely prescribe second-generation antiseizure medications to control unprovoked seizures while minimizing severe adverse effects. Consequently, the clinical application of levetiracetam in pediatric epilepsy has expanded markedly over the past two decades. Prescribers frequently choose this agent due to its predictable linear pharmacokinetics, rapid titration schedule, and minimal hepatic cytochrome P450 interactions. However, whether clinical trial evidence firmly supports its superiority over conventional antiseizure medications remains an active debate. A recent landmark systematic review and meta-analysis published in Neurology evaluated randomized controlled trials to clarify these therapeutic uncertainties.

Evaluating Levetiracetam in Pediatric Epilepsy: Evidence and Rationale

Clinicians often select levetiracetam because it offers convenient oral dosing formulations and favorable pharmacokinetic properties. Furthermore, physicians can rapidly achieve therapeutic dosing without prolonged dose escalation. This rapid titration proves particularly useful during acute presentations or initial management of seizure clusters. In addition, the molecule binds specifically to the synaptic vesicle protein SV2A, inhibiting presynaptic neurotransmitter exocytosis. Because it does not induce or inhibit hepatic microsomal enzymes, it creates minimal drug interaction risk when combined with other agents.

Nevertheless, observational popularity does not automatically equal superior clinical efficacy in randomized clinical trials. To address this knowledge gap, investigators systematically analyzed 25 randomized controlled trials encompassing 4,070 participants aged 16 years or younger. The systematic review identified trials evaluating seizure freedom and 50% responder rates across both monotherapy and adjunctive regimens. Notably, 23 of these trials contributed directly to pooled quantitative meta-analyses. The overall patient cohort included 43.8% female participants and spanned both pediatric-only cohorts and mixed-age populations. Consequently, this rigorous synthesis provides one of the most comprehensive evaluations of childhood epilepsy outcomes available today. Physicians must examine these comparative outcomes critically before making first-line prescribing choices.

Efficacy as Add-On Therapy Versus Placebo

When investigators examined placebo-controlled and no-therapy-controlled trials, levetiracetam demonstrated unequivocal clinical benefit. Most of these trials evaluated the drug as an adjunctive treatment in children experiencing drug-resistant seizures. For instance, children receiving levetiracetam achieved significantly higher seizure freedom rates compared to those receiving placebo. Specifically, the pooled risk difference for seizure freedom reached 11.0% with a 95% confidence interval of 5.3% to 16.7%. Therefore, the therapeutic intervention produced a meaningful absolute reduction in seizure recurrence across treatment cohorts.

Similarly, responder rates showed substantial clinical advantages in these adjunctive trial cohorts. Investigators defined responders as patients achieving at least a 50% reduction in seizure frequency during the maintenance phase. In this primary outcome, levetiracetam achieved a risk difference of 24.3% compared to placebo. Furthermore, this positive effect remained remarkably consistent across diverse seizure types and varied age brackets. Pediatric neurologists can therefore feel confident when prescribing this drug as an add-on therapy for refractory focal or generalized seizures. These findings confirm that the molecule actively suppresses epileptic activity when background medications prove insufficient.

Head-to-Head Comparisons: Active Antiseizure Medication Regimens

Although levetiracetam clearly outperforms placebo, its superiority over active comparator drugs remains unproven. In active-comparator trials, which primarily evaluated monotherapy regimens, levetiracetam showed no overall advantage. For example, the pooled risk difference for seizure freedom was -2.4% with a 95% confidence interval spanning -5.6% to 0.7%. Thus, the drug failed to demonstrate superior efficacy when researchers compared it directly against established antiseizure medications.

Moreover, responder rates in active-comparator trials showed a similar absence of superiority. The risk difference for responder rates was -7.4%, with a wide confidence interval ranging from -23.0% to 8.1%. Consequently, clinicians cannot assume that newer antiseizure agents will necessarily outperform traditional options such as carbamazepine or valproate. In fact, large pragmatic studies like SANAD II showed that valproate achieved superior 12-month remission rates in generalized epilepsy. Similarly, lamotrigine demonstrated superior cost-effectiveness and sustained remission in newly diagnosed focal epilepsy. Therefore, pediatricians should recognize that while levetiracetam is an effective option, it does not consistently surpass established therapies in pediatric monotherapy.

Methodological Quality and Risk of Bias Considerations

Evaluating the methodological rigor of the included trials reveals critical caveats for interpreting these results. Cochrane Risk of Bias assessments revealed that 14 of the 25 included trials possessed a high risk of bias. Consequently, publication bias and performance bias could distort therapeutic estimates across the broader literature. When researchers conducted sensitivity analyses restricted to low risk-of-bias trials, a striking pattern emerged. Specifically, the benefit over placebo remained robust, but levetiracetam showed a statistically significant disadvantage against active comparators.

Furthermore, substantial heterogeneity across trial designs complicates direct clinical translation. Many studies utilized short observation windows, failing to capture long-term developmental and cognitive outcomes in growing children. In addition, only 16 of the 25 trials evaluated pediatric-only populations, comprising 1,380 children. While findings in pediatric-only trials aligned with the overall pooled results, the limited volume of high-quality comparative data warrants caution. Clinicians must therefore interpret promotional efficacy claims carefully and avoid extrapolating short-term surrogate metrics into lifelong seizure remission.

Clinical Implications for Pediatric Practice in India

These meta-analytic findings carry immense practical significance for healthcare professionals practicing in resource-constrained environments like India. Pediatricians in outpatient clinics frequently manage children with new-onset seizures, febrile status, or established focal epilepsy. Given its rapid intravenous administration and lack of serious cutaneous adverse reactions, clinicians often favor levetiracetam over carbamazepine or phenytoin. However, older generic medications like valproate and carbamazepine remain significantly more affordable and widely available in rural government facilities.

Moreover, healthcare providers must weigh neurobehavioral adverse profiles when selecting long-term monotherapy in school-going children. Although levetiracetam avoids drug-induced hepatic injury and Stevens-Johnson syndrome, it can precipitate irritability, aggression, and mood instability in vulnerable pediatric patients. Conversely, sodium valproate poses teratogenic risks in adolescent females but provides exceptional control for generalized genetic epilepsies. Therefore, Indian clinicians should personalize drug selection based on seizure semiology, family economic resources, and behavioral risk factors rather than adopting levetiracetam as a default monotherapy.

Optimizing Individualized Care and Future Directions

Optimizing seizure management in children requires balancing efficacy, safety, cognitive outcomes, and financial feasibility. While levetiracetam clearly represents a potent adjunctive treatment for difficult seizures, evidence does not justify its automatic use as superior monotherapy. Instead, established guidelines from the International League Against Epilepsy emphasize tailoring initial monotherapy to specific epileptic syndromes. Clinicians must conduct careful syndromic classification using electroencephalography and neuroimaging before initiating long-term pharmacotherapy.

Furthermore, future research must address current evidence gaps through well-designed, independent randomized trials. Investigators should prioritize pediatric-only cohorts, head-to-head active comparisons, and standardized long-term behavioral evaluations. Additionally, researchers should investigate pharmacogenomic markers to identify children at elevated risk of psychiatric side effects. Until such high-grade evidence emerges, practitioners should use levetiracetam thoughtfully within comprehensive, patient-centered epilepsy care protocols.

Frequently Asked Questions

Is levetiracetam effective as initial monotherapy in pediatric epilepsy?

Levetiracetam effectively reduces seizures, but current randomized clinical trial evidence shows that it does not outperform established antiseizure medications such as carbamazepine or valproate as initial monotherapy. Clinicians should carefully weigh syndrome-specific efficacy, behavioral profiles, and overall cost before choosing it as a first-line treatment for children.

How does levetiracetam compare to sodium valproate for generalized seizures?

Clinical trials indicate that sodium valproate provides superior long-term seizure freedom compared to levetiracetam in generalized and unclassified epilepsies. Although levetiracetam avoids metabolic and teratogenic complications, valproate remains the most efficacious first-line choice for generalized seizure types, except in adolescent females of childbearing potential where alternative agents are preferred.

What are the primary adverse effects clinicians should monitor with levetiracetam?

Clinicians should primarily monitor pediatric patients for behavioral and psychiatric adverse effects, including irritability, agitation, aggression, and mood changes. While levetiracetam causes fewer cognitive slowing effects and serious cutaneous rashes than traditional agents, parental counseling regarding neurobehavioral symptoms is essential during initial titration and ongoing maintenance therapy.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Balestrini S et al. Efficacy of Levetiracetam in Patients With Pediatric Epilepsy: A Systematic Review and Meta-Analysis. Neurology. 2026 Jun 23. doi: 10.1212/WNL.0000000000218080. PMID: 42202238.


2. Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375-1386.


3. Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1363-1374.


4. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551-563.